Abbott high-risk human papillomavirus test kit - Taiwan Registration 6d59243050b34151fe87256d33d333a5
Access comprehensive regulatory information for Abbott high-risk human papillomavirus test kit in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 3 medical device is registered under number 6d59243050b34151fe87256d33d333a5 and manufactured by ABBOTT MOLECULAR INC.. The authorized representative in Taiwan is ABBOTT LABORATORIES SERVICES LLC TAIWAN BRANCH (U.S.A.).
This page provides complete technical specifications, regulatory compliance details, 1 companies making similar products including ABBOTT GMBH & CO. Medical history, and 1 recent registrations in the same category. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Device Details
Product Details
This product is a qualitative in vitro test method that uses the automated Alinity m system to detect the DNA of 14 strains of high-risk human papillomavirus (HR HPV) in clinical specimens, including HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. The test of this product can clearly identify HPV types 16, 18 and 45, and can simultaneously detect other high-risk genotypes (31/33/52/58) and (35/39/51/56/59/66/68) that reach the level of clinically relevant infection. This product is suitable for: screening patients with cervical cytology results of ASC-US (undefined atypical squamous epithelial cells) to determine whether colposcopy is required. This test result does not prevent a woman from having a follow-up colposcopy. Auxiliary screening for cervical cytology to assess the presence or absence of high-risk HPV. Used in first-line screening to identify high-risk groups of women who are prone to cervical cancer or have high-grade disease. To assess the presence or absence of HPV type 16 or 18 with or without cervical cytology to identify women at high risk of developing cervical cancer or with high degree of disease. The test results of this product should be evaluated by the physician in cytology, medical history, other risk factors and professional guidelines as a guide for patient management.
C Immunology and microbiology
C.0004 Human papillomavirus serum reagent
Input;; QMS/QSD
Dates and Status
Sep 16, 2020
Sep 16, 2025

